SM-88 Shows Efficacy in Pancreatic, Prostate Cancers

Tony Hagen @oncobiz
Published: Thursday, Jun 13, 2019
Allyson Ocean, MD

Allyson Ocean, MD

Having a late-stage treatment for pancreatic cancer that avoids many of the adverse events (AEs) associated with chemotherapy would be a boon for patients. Investigators say they see that kind of potential in SM-88, a combination metabolic cancer treatment that in studies so far has demonstrated a relatively mild toxicity profile along with other benefits.

“We need better therapies, and if patients are in the second and third lines of treatment, they likely cannot tolerate chemotherapy, especially at the standard dose,” Allyson Ocean, MD, an investigator in the 88-Panc phase II trial of SM-88 in metastatic pancreatic cancer, told OncologyLive®.

In a May update on 88-Panc, investigators said overall survival of evaluable patients was “trending to be approximately double the reported survival of this patient population.” As reported at the 2019 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 9 of 28 evaluable patients (32%) were alive at 6 months or longer, with 1 patient having reached 1 year of survival. The expected survival for this patient population would ordinarily be 2 to 2.5 months.1

The 88-Panc pancreatic cancer trial (NCT03512756), which has tested 2 dose levels of SM-88, also demonstrated improved survival in patients with advanced pancreatic cancer. Of 19 evaluable patients with end-stage pancreatic cancer, 67.8% remained alive at a median follow-up of 4.3 months.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication